A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
View/ Open
Volume
185
Pagination
916 - 938.e58
DOI
10.1016/j.cell.2022.01.012
Journal
Cell
Issue
Metadata
Show full item recordAbstract
Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description of specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying COVID-19 severity in an integrated comparison with influenza and sepsis patients versus healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity involved cells, their inflammatory mediators and networks, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism, and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Systems-based integrative analyses including tensor and matrix decomposition of all modalities revealed feature groupings linked with severity and specificity compared to influenza and sepsis. Our approach and blood atlas will support future drug development, clinical trial design, and personalized medicine approaches for COVID-19.
Authors
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk; COvid-19 Multi-omics Blood ATlas (COMBAT) ConsortiumCollections
Language
Licence information
The following license files are associated with this item:
Related items
Showing items related by title, author, creator and subject.
-
COVID-19 susceptibility variants associate with blood clots, thrombophlebitis and circulatory diseases.
Papadopoulou, A; Musa, H; Sivaganesan, M; McCoy, D; Deloukas, P; Marouli, E (Public Library of Science, 2021-09-03)Epidemiological studies suggest that individuals with comorbid conditions including diabetes, chronic lung, inflammatory and vascular disease, are at higher risk of adverse COVID-19 outcomes. Genome-wide association studies ... -
Impact of COVID-19 on recorded blood pressure screening and hypertension management in England: an analysis of monthly changes in the quality and outcomes framework indicators in OpenSAFELY.
Wiedemann, M; Speed, V; Cunningham, C; Higgins, R; Curtis, HJ; Andrews, C; Fisher, L; Hopcroft, L; Rentsch, CT; Mahalingasivam, V (BMJ Publishing Group Ltd, 2024-08-30)BACKGROUND: The COVID-19 pandemic disrupted cardiovascular disease management in primary care in England. OBJECTIVE: To describe the impact of the pandemic on blood pressure screening and hypertension management based on ... -
COVID-19 serological survey using micro blood sampling.
Matthews, MM; Kim, TG; Shibata, S; Shibata, N; Butcher, C; Hyun, J; Kim, KY; Robb, T; Jheng, SS; Narita, M (Springer Nature, 2021-05-04)During August 2020, we carried out a serological survey among students and employees at the Okinawa Institute of Science and Technology Graduate University (OIST), Japan, testing for the presence of antibodies against ...